Tanya M Petterson1, Randolph S Marks2, Aneel A Ashrani3, Kent R Bailey1, John A Heit4. 1. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic Rochester, MN, United States. 2. Division of Medical Oncology, Department of Oncology, Mayo Clinic Rochester, MN, United States. 3. Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, MN, United States. 4. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic Rochester, MN, United States; Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, MN, United States; Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic Rochester, MN, United States. Electronic address: heit.john@mayo.edu.
Abstract
BACKGROUND: The risk of venous thromboembolism (VTE) by cancer site is uncertain. OBJECTIVE: To estimate VTE risk by tumor site. METHODS: We enumerated observed active cancers by cancer site for Olmsted County, MN residents with incident VTE over the 13-year period, 1988-2000 (n = 345 of 1417). We used 1988-2000 Iowa State Surveillance, Epidemiology, and End Results (SEER) data to estimate the expected age-specific prevalence of cancer by cancer site for all VTE cases; standardized Morbidity Ratios (SMR) for each cancer site were estimated by dividing the observed number of cancers in the VTE incident cohort by the expected number. Relative risk regression was used to model the observed number of cancers of each site, adjusting for the expected value based on SEER prevalence data, using generalized linear regression with a Poisson error and the natural log of the age- and sex-group expected count as an offset. RESULTS: For men and women with VTE, all cancer sites had an increased SMR, ranging from 4.1 for head neck cancer to 47.3 for brain cancer. Among women, the SMR for breast, ovarian and other gynecologic cancers were 8.4, 13.0 and 8.4, respectively; for men, prostate cancer SMR was 7.9. Adjusting for age and sex, the relative risk (RR) of cancer in VTE cases was associated with cancer site in a multivariable model (p < 0.001). Adjusting for age and sex, pancreatic, brain, other digestive cancers, and lymphoma had significantly higher RRs than the grouped comparison cancers. CONCLUSIONS: Incident VTE risk can be stratified by cancer site.
BACKGROUND: The risk of venous thromboembolism (VTE) by cancer site is uncertain. OBJECTIVE: To estimate VTE risk by tumor site. METHODS: We enumerated observed active cancers by cancer site for Olmsted County, MN residents with incident VTE over the 13-year period, 1988-2000 (n = 345 of 1417). We used 1988-2000 Iowa State Surveillance, Epidemiology, and End Results (SEER) data to estimate the expected age-specific prevalence of cancer by cancer site for all VTE cases; standardized Morbidity Ratios (SMR) for each cancer site were estimated by dividing the observed number of cancers in the VTE incident cohort by the expected number. Relative risk regression was used to model the observed number of cancers of each site, adjusting for the expected value based on SEER prevalence data, using generalized linear regression with a Poisson error and the natural log of the age- and sex-group expected count as an offset. RESULTS: For men and women with VTE, all cancer sites had an increased SMR, ranging from 4.1 for head neck cancer to 47.3 for brain cancer. Among women, the SMR for breast, ovarian and other gynecologic cancers were 8.4, 13.0 and 8.4, respectively; for men, prostate cancer SMR was 7.9. Adjusting for age and sex, the relative risk (RR) of cancer in VTE cases was associated with cancer site in a multivariable model (p < 0.001). Adjusting for age and sex, pancreatic, brain, other digestive cancers, and lymphoma had significantly higher RRs than the grouped comparison cancers. CONCLUSIONS: Incident VTE risk can be stratified by cancer site.
Authors: Sigurdur Y Kristinsson; Ruth M Pfeiffer; Magnus Björkholm; Lynn R Goldin; Sam Schulman; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren Journal: Blood Date: 2010-03-18 Impact factor: 22.113
Authors: F Dentali; W Ageno; M Giorgi Pierfranceschi; M G Pierfranceschi; D Imberti; A Malato; C Nitti; A Salvi; S Siragusa; A Squizzato; J Vitale; G Agnelli Journal: J Thromb Haemost Date: 2011-05 Impact factor: 5.824
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Am J Epidemiol Date: 2011-03-23 Impact factor: 4.897
Authors: Sigrid K Braekkan; Knut H Borch; Ellisiv B Mathiesen; Inger Njølstad; Tom Wilsgaard; John-Bjarne Hansen Journal: Am J Epidemiol Date: 2010-04-23 Impact factor: 4.897
Authors: D P Cronin-Fenton; F Søndergaard; L A Pedersen; J P Fryzek; K Cetin; J Acquavella; J A Baron; H T Sørensen Journal: Br J Cancer Date: 2010-09-14 Impact factor: 7.640
Authors: Cynthia L Leibson; Jack Needleman; Peter Buerhaus; John A Heit; L Joseph Melton; James M Naessens; Kent R Bailey; Tanya M Petterson; Jeanine E Ransom; Marcelline R Harris Journal: Med Care Date: 2008-02 Impact factor: 2.983
Authors: I A Naess; S C Christiansen; P Romundstad; S C Cannegieter; F R Rosendaal; J Hammerstrøm Journal: J Thromb Haemost Date: 2007-04 Impact factor: 5.824
Authors: L Lefebvre; E Noyon; D Georgescu; V Proust; C Alexandru; M Leheurteur; J C Thery; L Savary; O Rigal; F Di Fiore; C Veyret; F Clatot Journal: Support Care Cancer Date: 2015-09-05 Impact factor: 3.603
Authors: Aneel A Ashrani; Rachel E Gullerud; Tanya M Petterson; Randolph S Marks; Kent R Bailey; John A Heit Journal: Thromb Res Date: 2016-01-05 Impact factor: 3.944
Authors: Ian A Buchanan; Michelle Lin; Daniel A Donoho; Arati Patel; Li Ding; Arun P Amar; Steven L Giannotta; William J Mack; Frank Attenello Journal: World Neurosurg Date: 2018-11-20 Impact factor: 2.104
Authors: Eeva Haapio; T Kiviniemi; H Irjala; P Koivunen; J K E Airaksinen; I Kinnunen Journal: Eur Arch Otorhinolaryngol Date: 2016-07-04 Impact factor: 2.503